$0.45 Earnings Per Share Expected for Qiagen (NYSE:QGEN) This Quarter

Analysts expect Qiagen (NYSE:QGENGet Rating) to post $0.45 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Qiagen’s earnings, with the lowest EPS estimate coming in at $0.44 and the highest estimate coming in at $0.49. Qiagen reported earnings of $0.67 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 32.8%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Qiagen will report full-year earnings of $2.10 per share for the current fiscal year, with EPS estimates ranging from $2.05 to $2.22. For the next financial year, analysts expect that the business will post earnings of $2.16 per share, with EPS estimates ranging from $2.08 to $2.23. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Qiagen.

Qiagen (NYSE:QGENGet Rating) last issued its quarterly earnings data on Tuesday, April 26th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.09. The company had revenue of $628.39 million for the quarter, compared to analyst estimates of $589.95 million. Qiagen had a net margin of 26.61% and a return on equity of 20.71%. During the same period in the prior year, the firm earned $0.66 earnings per share.

A number of equities analysts recently commented on QGEN shares. DZ Bank raised shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Monday, January 17th. Zacks Investment Research raised shares of Qiagen from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Friday, April 22nd. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Qiagen presently has an average rating of “Buy” and a consensus target price of $52.92.

Shares of QGEN opened at $46.13 on Wednesday. Qiagen has a fifty-two week low of $41.32 and a fifty-two week high of $58.00. The firm has a market capitalization of $10.47 billion, a PE ratio of 18.02, a PEG ratio of 2.15 and a beta of 0.23. The company’s 50-day moving average is $46.90 and its 200-day moving average is $50.37. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.90 and a quick ratio of 1.58.

A number of institutional investors have recently added to or reduced their stakes in QGEN. CWM LLC increased its stake in shares of Qiagen by 446.2% in the 1st quarter. CWM LLC now owns 579 shares of the company’s stock valued at $28,000 after acquiring an additional 473 shares in the last quarter. Masso Torrence Wealth Management Inc. bought a new stake in shares of Qiagen in the 4th quarter valued at $30,000. Pacer Advisors Inc. increased its stake in shares of Qiagen by 85.0% in the 4th quarter. Pacer Advisors Inc. now owns 592 shares of the company’s stock valued at $33,000 after acquiring an additional 272 shares in the last quarter. O Shaughnessy Asset Management LLC increased its stake in shares of Qiagen by 75.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 650 shares of the company’s stock valued at $34,000 after acquiring an additional 280 shares in the last quarter. Finally, UMB Bank N A MO bought a new stake in shares of Qiagen in the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 55.85% of the company’s stock.

About Qiagen (Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Read More

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.